drugset
drugset / Trial / NCT00492388

Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients

NCT00492388 ↗

Phase 3 Terminated 2 enrolled Pfizer
RandomizedCrossoverQuadruple-blindTreatment

Summary

To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.

Timeline

Start
2007-06
Primary completion
2011-08
Completion
2011-08

Outcome

Outcome not reported

Stopped (Business): “Business decision not to continue development”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule — Intranasal

Indications

cancer